These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38003967)

  • 21. ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma.
    Babikir H; Wang L; Shamardani K; Catalan F; Sudhir S; Aghi MK; Raleigh DR; Phillips JJ; Diaz AA
    Genome Biol; 2021 Nov; 22(1):311. PubMed ID: 34763709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
    Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
    Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas.
    Grandin N; Pereira B; Cohen C; Billard P; Dehais C; Carpentier C; Idbaih A; Bielle F; Ducray F; Figarella-Branger D; Delattre JY; Sanson M; Lomonte P; Poncet D; Verrelle P; Charbonneau M;
    Acta Neuropathol Commun; 2019 Nov; 7(1):175. PubMed ID: 31706351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Characteristics of Thalamic Gliomas in Adults.
    Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q
    J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy.
    Dumke R; Dumke C; Eberle F; Nimsky C; Keber U; Engenhart-Cabillic R; Lautenschläger S
    Strahlenther Onkol; 2022 Oct; 198(10):892-906. PubMed ID: 35612598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gliomas - An experience based on molecular markers.
    Sarma S; Khonglah Y; Mishra J; Kakati A; Phukan P
    J Family Med Prim Care; 2021 Mar; 10(3):1341-1346. PubMed ID: 34041176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ATRX in Diffuse Gliomas With its Mosaic/Heterogeneous Expression in a Subset.
    Purkait S; Miller CA; Kumar A; Sharma V; Pathak P; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Fulton RS; Kale SS; Dahiya S; Sarkar C
    Brain Pathol; 2017 Mar; 27(2):138-145. PubMed ID: 26833422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas.
    Bouvier-Labit C; Chinot O; Ochi C; Gambarelli D; Dufour H; Figarella-Branger D
    Neuropathol Appl Neurobiol; 1998 Oct; 24(5):381-8. PubMed ID: 9821169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.
    Chaurasia A; Park SH; Seo JW; Park CK
    J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation.
    Armocida D; Frati A; Salvati M; Santoro A; Pesce A
    Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience.
    Alan O; Telli TA; Tuylu TB; Arikan R; Demircan NC; Ercelep O; Kaya S; Babacan NA; Atasoy BM; Bozkurt S; Bayri Y; Gul D; Ekinci G; Ziyal I; Dane F; Yumuk PF
    J Oncol Pharm Pract; 2021 Mar; 27(2):329-339. PubMed ID: 32349641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
    Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
    Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
    Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
    J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High frequency of H3K27M immunopositivity in adult thalamic glioblastoma.
    Rao S; Kanuri NN; Nimbalkar V; Arivazhagan A; Santosh V
    Neuropathology; 2019 Apr; 39(2):78-84. PubMed ID: 30937985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance.
    Uppar AM; Sugur H; Prabhuraj AR; Rao MB; Devi BI; Sampath S; Arivazhagan A; Santosh V
    Childs Nerv Syst; 2019 Sep; 35(9):1537-1545. PubMed ID: 31152217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between IDH, ATRX, and TERT promoter mutations in glioma.
    Ohba S; Kuwahara K; Yamada S; Abe M; Hirose Y
    Brain Tumor Pathol; 2020 Apr; 37(2):33-40. PubMed ID: 32227259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.